よむ、つかう、まなぶ。
会議資料 (88 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00036.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第62回 3／13）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；II-5
metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan. Ann
Nucl Med 2020; 34: 397-406.
38. Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Ikawa Y, et al. High-dose 131I-mIBG
as consolidation therapy in pediatric patients with relapsed neuroblastoma and
ganglioneuroblastoma: the Japanese experience. Ann Nucl Med 2020; 34: 840-6.
39. Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta
iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014; 50: 80115.
40. Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, et al. Neuroblastoma.
Pediatr Blood Cancer 2021; 68 Suppl 2: e28473.
41. Kayano D, Kinuya S. Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports
so far and future perspective. ScientificWorldJournal 2015; 2015: 189135.
42. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in Neuroblastoma Diagnostic Imaging and
Therapy. Radiographics 2016; 36: 258-78.
43. Olecki E, Grant CN. MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg
2019; 28: 150859.
44. Grünwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other
neuroendocrine tumors. Semin Nucl Med 2010; 40: 153-63.
45. Parisi MT, Eslamy H, Park JR, Shulkin BL, Yanik GA. ¹³¹I-Metaiodobenzylguanidine
Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. Semin
Nucl Med 2016; 46: 184-202.
46. Rafael MS, Cohen-Gogo S, Irwin MS, Vali R, Shammas A, Morgenstern DA. Theranostics in
Neuroblastoma. PET Clin 2021; 16: 419-27.
47. Park J, Hogarty M, Bagatell R, Schleiermacher G, Mossé Y, Maris J. Neuroblastoma.
In: Blaney S, Adamson P, Helman L, editors. Pizzo and Poplack's Pediatric Oncology. 8th ed:
Wolters Kluwer; 2021.
48. Matthay KK, Valteau-Couanet D. High-Risk Neuroblastoma and Current Protocols. In:
Sarnacki S, Pio L, editors. Neuroblastoma: Clinical and Surgical Management: Springer; 2020.
49. Norepinephrine-Targeted Therapy. In: Ray S, editor. Neuroblastoma: Molecular Mechanisms
and Therapeutic Interventions: Elsevier; 2019.
50. Shohet JM, Lowas SR, Nuchtern JG. Treatment and prognosis of neuroblastoma. 2024. In:
UpToDate [Internet]. Wolters Kluwer.
51. Broudeur GM, Maris JM. Neuroblastoma. In: Rudolph CD, Rudolph AM, editors. Rudolph's
Pediatrics. 21st ed: McGraw-Hill; 2003.
52. 萱野 大樹. 131I-MIBG による悪性神経内分泌腫瘍の核医学治療. In: 日本核医学技術学
会, editor. 新核医学技術総論［臨床編］: 山城印刷株式会社; 2020.
53. 萱野 大樹. 131I-MIBG 治療. 8th: 中外医学社; 2023. 新核医学テキスト.
33
88 / 235
metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan. Ann
Nucl Med 2020; 34: 397-406.
38. Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Ikawa Y, et al. High-dose 131I-mIBG
as consolidation therapy in pediatric patients with relapsed neuroblastoma and
ganglioneuroblastoma: the Japanese experience. Ann Nucl Med 2020; 34: 840-6.
39. Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta
iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014; 50: 80115.
40. Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, et al. Neuroblastoma.
Pediatr Blood Cancer 2021; 68 Suppl 2: e28473.
41. Kayano D, Kinuya S. Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports
so far and future perspective. ScientificWorldJournal 2015; 2015: 189135.
42. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in Neuroblastoma Diagnostic Imaging and
Therapy. Radiographics 2016; 36: 258-78.
43. Olecki E, Grant CN. MIBG in neuroblastoma diagnosis and treatment. Semin Pediatr Surg
2019; 28: 150859.
44. Grünwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other
neuroendocrine tumors. Semin Nucl Med 2010; 40: 153-63.
45. Parisi MT, Eslamy H, Park JR, Shulkin BL, Yanik GA. ¹³¹I-Metaiodobenzylguanidine
Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. Semin
Nucl Med 2016; 46: 184-202.
46. Rafael MS, Cohen-Gogo S, Irwin MS, Vali R, Shammas A, Morgenstern DA. Theranostics in
Neuroblastoma. PET Clin 2021; 16: 419-27.
47. Park J, Hogarty M, Bagatell R, Schleiermacher G, Mossé Y, Maris J. Neuroblastoma.
In: Blaney S, Adamson P, Helman L, editors. Pizzo and Poplack's Pediatric Oncology. 8th ed:
Wolters Kluwer; 2021.
48. Matthay KK, Valteau-Couanet D. High-Risk Neuroblastoma and Current Protocols. In:
Sarnacki S, Pio L, editors. Neuroblastoma: Clinical and Surgical Management: Springer; 2020.
49. Norepinephrine-Targeted Therapy. In: Ray S, editor. Neuroblastoma: Molecular Mechanisms
and Therapeutic Interventions: Elsevier; 2019.
50. Shohet JM, Lowas SR, Nuchtern JG. Treatment and prognosis of neuroblastoma. 2024. In:
UpToDate [Internet]. Wolters Kluwer.
51. Broudeur GM, Maris JM. Neuroblastoma. In: Rudolph CD, Rudolph AM, editors. Rudolph's
Pediatrics. 21st ed: McGraw-Hill; 2003.
52. 萱野 大樹. 131I-MIBG による悪性神経内分泌腫瘍の核医学治療. In: 日本核医学技術学
会, editor. 新核医学技術総論［臨床編］: 山城印刷株式会社; 2020.
53. 萱野 大樹. 131I-MIBG 治療. 8th: 中外医学社; 2023. 新核医学テキスト.
33
88 / 235